Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1993 Sep;93(3):452–455. doi: 10.1111/j.1365-2249.1993.tb08200.x

IgG inhibits the increase of platelet-associated C3 stimulated by anti-platelet antibodies

S Nomura, Y Miyazaki, T Miyake, K Yamaguchi, H Kido, T Kawakatsu, T Fukuroi, H Kagawa, M Suzuki, M Yanabu, T Kokawa
PMCID: PMC1554901  PMID: 8370175

Abstract

We investigated the increase of platelet-associated IgG and complement component 3 (C3) caused by the in vitro action of anti-platelet MoAbs, and the effect of mouse and human IgG on these events. Anti-glycoprotein IIb/IIIa and anti-glycoprotein Ib MoAbs caused a slight increase of C3, but not of platelet-associated IgG. In contrast, anti-CD9 and anti-Fcγ II receptor MoAbs caused an increase of both platelet-associated C3 and IgG. In particular, three MoAbs which activated the complement system caused a marked increase of C3. When platelet-rich plasma was treated with aspirin and prostaglandin E1 before incubation with antibodies, the increase of platelet-associated IgG was inhibited in all cases. In contrast, the increase of platelet-associated C3 was scarcely influenced. These results suggest that the binding to platelets of platelet-activating antibodies caused the increase expression of IgG molecules on the platelet surface and a possible increase of platelet-associated IgG. However, the increase of platelet-associated C3 appeared to depend on specific characteristics of the antibodies tested, such as a complement-activating effect. In addition, intact mouse or human IgG inhibited the increase of platelet-associated C3 caused by complement-activating antibodies, while F(ab')2 mouse or human IgG had no such effect. This suggested that the Fc portion of IgG may block the increase of C3 mediated by anti-platelet antibodies.

Full text

PDF
452

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnott J., Horsewood P., Kelton J. G. Measurement of platelet-associated IgG in animal models of immune and nonimmune thrombocytopenia. Blood. 1987 May;69(5):1294–1299. [PubMed] [Google Scholar]
  2. Basta M., Fries L. F., Frank M. M. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood. 1991 Jan 15;77(2):376–380. [PubMed] [Google Scholar]
  3. Basta M., Kirshbom P., Frank M. M., Fries L. F. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest. 1989 Dec;84(6):1974–1981. doi: 10.1172/JCI114387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Basta M., Langlois P. F., Marques M., Frank M. M., Fries L. F. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood. 1989 Jul;74(1):326–333. [PubMed] [Google Scholar]
  5. Bussel J. B., Pham L. C., Aledort L., Nachman R. Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin. Blood. 1988 Jul;72(1):121–127. [PubMed] [Google Scholar]
  6. Capel P. J., Groeneboer O., Grosveld G., Pondman K. W. The binding of activated C3 to polysaccharides and immunoglobulins. J Immunol. 1978 Dec;121(6):2566–2572. [PubMed] [Google Scholar]
  7. Cines D. B., Schreiber A. D. Immune thrombocytopenia. Use of a Coombs antiglobulin test to detect IgG and C3 on platelets. N Engl J Med. 1979 Jan 18;300(3):106–111. doi: 10.1056/NEJM197901183000302. [DOI] [PubMed] [Google Scholar]
  8. Cines D. B., Wilson S. B., Tomaski A., Schreiber A. D. Platelet antibodies of the IgM class in immune thrombocytopenic purpura. J Clin Invest. 1985 Apr;75(4):1183–1190. doi: 10.1172/JCI111814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dixon R., Rosse W., Ebbert L. Quantitative determination of antibody in idiopathic thrombocytopenic purpura. Correlation of serum and platelet-bound antibody with clinical response. N Engl J Med. 1975 Jan 30;292(5):230–236. doi: 10.1056/NEJM197501302920503. [DOI] [PubMed] [Google Scholar]
  10. George J. N. Platelet immunoglobulin G: its significance for the evaluation of thrombocytopenia and for understanding the origin of alpha-granule proteins. Blood. 1990 Sep 1;76(5):859–870. [PubMed] [Google Scholar]
  11. Imbach P., Barandun S., d'Apuzzo V., Baumgartner C., Hirt A., Morell A., Rossi E., Schöni M., Vest M., Wagner H. P. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981 Jun 6;1(8232):1228–1231. doi: 10.1016/s0140-6736(81)92400-4. [DOI] [PubMed] [Google Scholar]
  12. Karpatkin S. Autoimmune thrombocytopenic purpura. Blood. 1980 Sep;56(3):329–343. [PubMed] [Google Scholar]
  13. Kayser W., Mueller-Eckhardt C., Bhakdi S., Ebert K. Platelet-associated complement C3 in thrombocytopenic states. Br J Haematol. 1983 Jul;54(3):353–363. doi: 10.1111/j.1365-2141.1983.tb02110.x. [DOI] [PubMed] [Google Scholar]
  14. McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1981 May 7;304(19):1135–1147. doi: 10.1056/NEJM198105073041904. [DOI] [PubMed] [Google Scholar]
  15. NIH conference. Pathophysiology of immune hemolytic anemia. Ann Intern Med. 1977 Aug;87(2):210–222. doi: 10.7326/0003-4819-87-2-210. [DOI] [PubMed] [Google Scholar]
  16. Nomura S., Nagata H., Oda K., Kokawa T., Yasunaga K. Effects of EDTA on the membrane glycoproteins IIb-IIIa complex--analysis using flow cytometry. Thromb Res. 1987 Jul 1;47(1):47–58. doi: 10.1016/0049-3848(87)90239-8. [DOI] [PubMed] [Google Scholar]
  17. Nomura S., Nagata H., Suzuki M., Kondo K., Ohga S., Kawakatsu T., Kido H., Fukuori T., Yamaguchi K., Iwata K. Microparticle generation during in vitro platelet activation by anti-CD9 murine monoclonal antibodies. Thromb Res. 1991 Jun 1;62(5):429–439. doi: 10.1016/0049-3848(91)90016-p. [DOI] [PubMed] [Google Scholar]
  18. Nomura S., Suzuki M., Kido H., Yamaguchi K., Fukuroi T., Yanabu M., Soga T., Nagata H., Kokawa T., Yasunaga K. Differences between platelet and microparticle glycoprotein IIb/IIIa. Cytometry. 1992;13(6):621–629. doi: 10.1002/cyto.990130610. [DOI] [PubMed] [Google Scholar]
  19. Nomura S., Yamaguchi K., Kido H., Kawakatsu T., Iwata K., Fukuroi T., Suzuki M., Yanabu M., Soga T., Nagata H. New monoclonal anti-human Fc gamma receptor II antibodies induce platelet aggregation. Clin Exp Immunol. 1991 Oct;86(1):179–184. doi: 10.1111/j.1365-2249.1991.tb05792.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nomura S., Yanabu M., Fukuroi T., Kido H., Kawakatsu T., Yamaguchi K., Suzuki M., Kokawa T., Yasunaga K. Anti-glycoprotein IIb/IIIa autoantibodies are reversibly internalized into platelets in idiopathic (autoimmune) thrombocytopenic purpura. Autoimmunity. 1992;13(2):133–140. doi: 10.3109/08916939209001914. [DOI] [PubMed] [Google Scholar]
  21. Nomura S., Yanabu M., Kido H., Fukuroi T., Yamaguchi K., Soga T., Nagata H., Kokawa T., Yasunaga K. Antiplatelet autoantibody-related microparticles in patients with idiopathic (autoimmune) thrombocytopenic purpura. Ann Hematol. 1991 Apr;62(4):103–107. doi: 10.1007/BF01702922. [DOI] [PubMed] [Google Scholar]
  22. Oyaizu N., Yasumizu R., Miyama-Inaba M., Nomura S., Yoshida H., Miyawaki S., Shibata Y., Mitsuoka S., Yasunaga K., Morii S. (NZW x BXSB)F1 mouse. A new animal model of idiopathic thrombocytopenic purpura. J Exp Med. 1988 Jun 1;167(6):2017–2022. doi: 10.1084/jem.167.6.2017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Panzer S., Szamait S., Bödeker R. H., Haas O. A., Haubenstock A., Mueller-Eckhardt C. Platelet-associated immunoglobulins IgG, IgM, IgA and complement C3 in immune and nonimmune thrombocytopenic disorders. Am J Hematol. 1986 Oct;23(2):89–99. doi: 10.1002/ajh.2830230203. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES